Clinical Pipeline
DA-1726
Obesity is a complex disease in which excessive body fat increases due to nutrient imbalance. Obesity is a medical problem requiring interventional treatment to manage and minimize the risk of other health problems, such as diabetes, high blood pressure, and heart disease, etc. Up to now, most weight loss drugs solely restrict nutrient intake.
DA-1726 is a long acting oxyntomodulin peptide analog that can bind and activate both glucagon-like peptide-1 (GLP-1) and glucagon receptors. Activation of GLP-1 and glucagon receptors suppresses appetite and reduces nutrient intake. In addition, activation of glucagon receptors in adipose tissue elicits fat burning. Thus, DA-1726, designed as a well-balanced dual agonist, induces weight loss while effectively improving body composition. Moreover, hypoglycemic effects induced by GLP-1 receptor activation were maintained. DA-1726 has a well understood mechanism of action, and, in pre-clinical mice models, resulted in improved weight loss compared to semaglutide (Wegovy®) and cotadutide (another OXM analogue). Additionally, in pre-clinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared to tirzepatide (Zepbound®) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide. DA-1726 also has therapeutic potential for MASH via ameliorating metabolic dysregulations.